SP-0637: The role of the radiation technologist in the Brachytherapy (BT) Service at the Gustave Roussy Institute  by Monnot, F. et al.
2nd ESTRO Forum 2013  S245 
	
clinical applications exemplified. Finally, future directions will be 
discussed.  
 
SP-0634   
Cine cone beam CT imaging with and without prior images 
S. Jiang1 
1University of California San Diego, Department of Radiation 
Oncology, La Jolla, USA  
 
Cone beam CT (CBCT) has been widely utilized for localizing daily 
tumor position and patient positioning in lung cancer radiotherapy. 
However, due to the respiratory motion during the CBCT scan, the 
tumor image is blurred and may introduce inaccuracy in treatment 
delivery. To solve this problem, and to obtain accurate daily lung 
tumor motion information, we have been developing cine CBCT 
technologies, either with or without prior images, to reconstruct a 
series of 3D CBCT images from a regular CBCT scan, corresponding to 
different breathing phases or time points during the scan. For the 
technology using prior images, we used 4DCT as training data. A 
deformable image registration is first carried out between among 
4DCT images resulting in deformation vector fields (DVFs). These DVFs 
are represented by a few eigenvectors and coefficients obtained from 
principal component analysis (PCA). The volumetric reconstruction 
from a CBCT projection is realized by optimizing the PCA coefficients 
such that the computed projection matches the measured CBCT 
projection. For the technology without prior images, we developed a 
novel algorithm to reconstruct  a 3D image corresponding to each 
CBCT projection, by effectively utilizing the underlying 
temporal coherence, such as periodicity or repetition, in all 
reconstructed 3D images. Assuming each column of the matrix U 
represents a CBCT image to be reconstructed and the total number of 
columns is the same as the number of projections, the central idea of 
our method is that U can be approximated well by a matrix whose 
rank is much smaller than the number of projections in the matrix 
factorization form U ≈ LR. The number of columns for the matrix L 
constraints the rank of approximation and hence implicitly imposing a 
temporal coherence condition among all the images in cine-CBCT. We 
further impose desired image properties by enforcing sparsity of 
the tight wavelet frame transform of L. In this matrix factorization 
formulation both the low rank approximation and the sparse 
representation in wavelet transform domain reduces the true degree 
of freedom of U significantly. A split Bregman method is used to solve 
the problem.  
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The standard treatment of locally advanced cervical cancer consists of 
external beam radiotherapy with concomitant cisplatin followed by 
intracavitary brachytherapy (BT). For decades BT has most often been 
based on radiographs with the BT dose prescribed to point A. 
In 2005 an adaptive target concept for BT based on 3D imaging was 
introduced by the GYN GEC-ESTRO working group addressing both the 
tumour extend at diagnosis – the Intermediate Risk Clinical Target 
Volume (IR CTV) as well as the remaining tumour at time of BT – the 
High Risk Clinical Target Volume (HR CTV).  
With the introduction of Image Guided Adaptive BT (IGABT) it is 
possible to move from point A to 3D dose volume prescription in terms 
of dose volume histogram (DVH) parameters. Furthermore, dose 
optimisation can be performed with modifications of standard loading 
patterns leading to an individually sculpted pear-shaped isodose 
tailored to the target and organs (OAR) at risk at time of BT. 
However, dose optimisation based on intracavitary (IC) BT applicators 
have limitations especially in large tumours with extensive 
parametrial involvement remaining at time of BT or in cases with 
unfavourable combination of topography between the HR CTV and the 
OAR. A solution is to add an interstitial (IS) component to the basic IC 
applicator. Studies with limited number of patients have shown that 
combined IC/IS BT improve the DVH parameters, but larger studies on 
clinical feasibility are sparse and widespread implementation of the 
IC/IS technique is so far limited. 
At present, promising mono-institutional data on IGABT for cervical 
cancer with high local control rates and limited morbidity have been 
published. Furthermore, several studies have established dose 
constrains for target as well as OAR.  
In order to achieve more experience on IGABT for cervical cancer, 
large-scale multi-studies such as the EMBRACE-study and 
RETROEMBRACE-study have been initiated. During the next years, data 
will mature for analysis and serve as benchmark for future IGABT in 
cervical cancer. 
The purpose of this lecture is to describe and explain the basic 
components behind the recommendations from the GYN GEC-ESTRO 
working group. Furthermore, it is aimed to review the literature on 
IGABT and describe outcome in terms of local control, survival and 
morbidity from published mono-institutional series of patients. 
Finally, it is aimed to describe the future directions in IGABT for 
cervical cancer. 
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Physics aspects of treatment planning for intracavitary w/o 
interstitial techniques in cervical cancer 
D. Berger1 
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For cervical cancer interstitial and intracavitary brachytherapy 
techniques are an option to treat the tumour sufficient by keeping the 
traditional pear-shaped isodose distribution. Improvement of target 
coverage and organs at risk sparing is determined by DVH parameters 
D90, D98 (D100) for the target and D2cc, D0.1cc for OAR. The major 
limitation in the optimization process is the dose to the adjacent 
OAR’s like sigmoid, rectum and bladder. As the pear-shaped dose 
distribution based on the intracavitary applicator can be enlarged to a 
certain extend only, additional needles are useful to push the isodose 
lines into the needed direction (Parametrium- pelvic side wall).  
The selection of the adequate application technique depends on the 
size and shape of the target volume at time of brachytherapy (after 
EBRT). With intracavitary techniques tumours which are limited to the 
cervix can be appropriately treated. Nevertheless, small tumours with 
unfavourable topographies within the pelvis (narrow anatomies with 
only a small distance from the tumour to the OAR bladder, rectum or 
sigmoid) may benefit from the use of additional needles. Over the last 
years “standard” intracavitary applicators have been modified in a 
way to allow insertion of needles through guiding holes, i.e. the 
“vaginal” part of the applicator (ring, ovoid or mould) serves as and 
interstitial template which is attached to the cervix. Other techniques 
use vaginal cylinders including oblique guiding holes or templates like 
the MUPIT or Syed. For vaginal cancer intravaginal templates exist. In 
interstitial treatment planning, traditionally, the Paris System rules 
are kept in mind. Different tools like inverse planning, graphical drag-
and-drop of isodose lines and other optimization techniques are 
available but should be handled with caution. The final dose 
distribution including high dose volumes should always be checked 
before irradiation. In situation of complex tumour configurations pre-
planning of the application technique with 3D imaging increases the 
quality of the implant and of the final treatment plan. 
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The BT Service, in terms of material, is composed of five pulsed dose 
rate (PDR) and one high dose rate (HDR) afterloaders. Interstitial, 
endocavitary and endoluminal BT are performed depending on the 
type and tumor localizations. The team consists of physicians, 
residents, medical physicists and radiation therapy technologists 
(RTTs). The presentation purpose is to describe the role and the work 
of an RTT in the treatment of patients with cervix cancers in our 
institute. 
Role of RTT: 
RTT plays a major role in a BT service. Essential for the team 
cohesion, she is working at the interface of the radiation oncologist, 
medical physicist, and patient. Present in all steps of the treatment, 
she participates to the consultation, preparation, implantation, 
dosimetry and treatment compliance. In order to improve the overall 
treatment conditions, a pre-therapeutic consultation is systematically 
performed by the RTT. The aim is to answer questions about 
hospitalization, radioactivity, management of pain and treatment 
itself. A picture book describing the different steps of the treatment 
was designed by RTT. This helps and allows a better understanding for 
patients. 
The technique used in our institute for the cervix BT consists of the 
vaginal mould technique. For each patient, a customized vaginal 
mould is created from a vaginal impression. The mould applicator 
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contains one intrauterine and two vaginal catheters. The presence of 
an RTT during the vaginal impression is essential as support to the 
radiation oncologist. Based on the tumour topography representation, 
the RTT is able to manufacture a personalized mould adapted to the 
patient anatomy. The catheters positions are placed according to the 
physician recommendations. 
Before each treatment, the RTT performs quality controls on the 
afterloader. These controls, made under physicist responsibility, 
include all safety tests, verification of source positioning and 
agreement between air kerma rate calculated by the afterloader at 
the date of treatment for the source and the one measured at the 
date of calibration. 
In the operating room, the RTT checks the patient’s identity and is in 
charge of the patient installation. She prepares the medico-surgical 
instrumentation table and assists the radiation oncologist during the 
procedure. At the end of the implantation, she fills the technical 
documentation and gives it to nurses.  
Once the implantation is performed, the patient is transferred to the 
MRI scanner. With the help of a physician, the RTT inserts MRI 
compatible dummy sources into the catheters allowing a visualization 
of the intrauterine and vaginal positions of the sources. The 
delineation and the dosimetry are realised on MRI images. In this 
optimized 3D dosimetry, the RTT takes part in every step of the 
treatment. She creates the patient file in the treatment planning 
system (TPS),imports, checks the MRI images, and reconstructs the 
cervix applicator. Following the dosimetry validation, she records 
treatment parameters on a register and informs the patient on her 
treatment before it starts. 
In conclusion we have shown that the RTT is involved in every step of 
the cervix BT treatment. Her role is crucial in the treatment workflow 
and needs specifics skills to be accomplished.  In addition to 
versatility, the RTT needs a rigor, thoroughness, empathy and 
patience.  
   
 SYMPOSIUM: LYMPHOMA: TO IRRADIATE OR NOT TO 
IRRADIATE  
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Role of RT in Hodgkin lymphoma in the PET-era (with a link to the 
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The question is whether PET response-adapted strategies can be 
devised to deliver radiation treatments to a selected group of 
patients. The backdrop of this persistent and sometimes emotional 
quest is complex but can be summarized as follows: first, combined 
modality treatments are superior to chemotherapy alone in terms of 
overall and progression-free survival, as demonstrated by a recent 
meta-analysis (1). Second, chemotherapy is very efficacious. Third, 
radiation treatments be get late complications such as second tumors 
and cardiovascular diseases. Fourth, the late effects of ABVD might 
have been grossly underestimated (2). PET response-adapted 
strategies can be implemented if PET predictive values are highly 
significant and reliable. Preliminary conclusions can be obtained from 
a small number of non randomized studies after completion of 
planned treatments. The negative predictive value (NPV) for the 
intermediary and end of treatment PET assessments was excellent (> 
95%). In contrast, the positive predictive value (PPV) was extremely 
low (15%-20%) and therefore systematic biopsies are always highly 
recommended to confirm the diagnosis. As, in all likelihood,the role 
of radiation therapy in advanced Hodgkin lymphoma will remain 
extremely reduced, we will focus on ongoing trials in early-stage 
Hodgkin lymphoma. Currently, there are 4 randomized trials and one 
non-randomized study. The relatively small Vancouver non-
randomized study suggested that radiotherapy could be avoided in 
approximately 80% of the patients with a negative PET after 2 ABVD 
cycles. Among the randomized trials, very favorable Hodgkin 
lymphoma patients were entered in 2 of them (mostly IA and IIA: 
GHSG and the UK Rapid trial). In two others (EORTC-LYSA-FIL H10, 
Euronet-PHLC-C1), all early stages were included. The preliminary 
results of the UK Rapid trial suggest that radiotherapy was not 
necessary in patients with a negative PET scan after 2 to 3 cycles of 
ABVD (75% of the patients). On the other hand, an interim analysis of 
the much larger H10 trial demonstrated that PET-negative patients 
after 2 ABVD cycles had a significantly higher risk of local recurrence 
or progression. The experimental arm with PET-negative patients was 
prematurely closed for further accrual. The very preliminary results of 
the ongoing Euronet trial, suggest that radiation treatments were not 
performed in a substantial number of PET-negative patients (only 40% 
of the French patients received radiation therapy: 26%, 41%, and 50% 
in the TG1, TG2, and TG3 groups respectively). 
Conclusions. Very preliminary results seem to suggest that an early 
PET response might provide a reliable basis for individualized 
response-adapted treatment strategies. However, the final results of 
the ongoing randomized trials should be awaited before drawing 
definite conclusions that may be applicable in clinical practice. 
Moreover, it must be emphasized that difficulties remain: the still 
persistent variability of PET assessment and the absence of a clear 
understanding of the underlying biological mechanisms of PET avidity. 
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Radiotherapy (RT) is the most effective single modality for local 
control of non Hodgkin lymphoma (NHL), and it is an important 
component of the treatment of many patients. The previously applied 
wide field and involved field techniques are no longer relevant, and 
have been replaced by defined volumes based on modern imaging and 
the ICRU concepts, the so-called involved site RT. Moreover, there is 
increasing evidence that the RT doses used in the past are higher than 
necessary for disease control. The goal of modern smaller field 
radiotherapy is to reduce both treatment volume and treatment dose 
whilst maintaining efficacy and minimising acute and late sequelae. 
B-cell lymphomas constitute 85-90 % of lymphomas in adults. The 
large majority expresses CD20 antigen. The development of anti-CD20 
antibodies, first Rituximab approved in 1997, significantly improved 
treatment results when added to standard chemotherapy for patients 
with advanced disease. The question is now if the role of RT in B-cell 
lymphomas has changed. 
Diffuse large B-cell lymphoma (DLBCL) is the most common 
aggressive lymphoma. For stage I-II patients without bulk or elevated 
LDH, standard treatment based on somewhat conflicting randomized 
trials was brief chemotherapy (3 cycles of CHOP) followed by IFRT. No 
randomized trial is available using R-CHOP, but retrospective analyses 
indicate that RT improves outcome also in this setting. For patients 
with risk factors 3 cycles of R-CHOP may not be enough. A positive 
PET-scan after R-CHOP has a low predictive value, and most PET+ 
cases achieve complete remission (CR) after RT. For advanced disease 
earlier studies showed benefit from RT in patients achieving a CR in 
some studies but not in others, whereas patients achieving only partial 
remission (PR) benefit from RT to residual masses. However, recent 
randomized studies in patients treated with Rituximab indicate that 
RT to initial bulk or extranodal disease, even in CR patients, improves 
outcome. Randomized evidence indicates that 30 Gy is a sufficient 
dose, at least in CR patients.  
Follicular lymphoma (FL) grade 1-2 is the most common indolent 
lymphoma. In early stage disease RT is still the only proven way for 
potential cure. Standard treatment is RT alone, and randomized 
evidence indicates that 24 Gy is a sufficient dose. Unfortunately, this 
treatment seems to be underused. For patients with advanced 
disease, if treatment is indicated, Rituximab with or without 
chemotherapy is given, but has not been shown to be curative. Low 
dose (2 Gy x 2) RT is an effective palliative treatment for locally 
symptomatic disease. 
Marginal zone lymphomas are indolent B-cell lymphomas, most often 
extranodal and localized. RT (24-30 Gy) is curative in the majority of 
localized cases, and is the preferred treatment (except for H. pylori 
positive gastric). Rituximab may be used if RT is contraindicated. 
Advanced disease is uncommon, no curative treatment exists, treated 
like FL. 
Mantle cell lymphomas are B-cell lymphomas with an aggressive 
behaviour. Very rarely these lymphomas are localized, and RT may be 
curative. No curative systemic treatment exists, and although 
Rituximab improves response rate and time to treatment failure it has 
little impact on survival. Advanced disease is incurable, but local 
palliative RT can be very effective. 
Primary cutaneous B-cell lymphomas are treated with local RT if 
solitary or regional. Only the aggressive type, DLBCL leg type, is also 
treated systemically (R-CHOP) for patients who can tolerate it. 
Patients with generalized disease are treated palliatively with 
Rituximab containing regimens, and local RT is given for palliation of 
symptoms.  
T-cell lymphomas are CD20 negative, and treatment is not influenced 
by the introduction of Rituximab. Most T-cell lymphomas present as 
advanced disease, RT has no role in the treatment except for 
palliation, and prognosis is poor. Exceptions are NK/T-cell lymphomas, 
cutaneous anaplastic large cell lymphomas, and mycosis fungoides, 
where RT is an important part of treatment.  
